CL2022001380A1 - Células madre mesenquimales con propiedades terapéuticas mejoradas - Google Patents

Células madre mesenquimales con propiedades terapéuticas mejoradas

Info

Publication number
CL2022001380A1
CL2022001380A1 CL2022001380A CL2022001380A CL2022001380A1 CL 2022001380 A1 CL2022001380 A1 CL 2022001380A1 CL 2022001380 A CL2022001380 A CL 2022001380A CL 2022001380 A CL2022001380 A CL 2022001380A CL 2022001380 A1 CL2022001380 A1 CL 2022001380A1
Authority
CL
Chile
Prior art keywords
mscs
stem cells
mesenchymal stem
therapeutic properties
improved therapeutic
Prior art date
Application number
CL2022001380A
Other languages
English (en)
Inventor
Luz Crawford Patricia
Contreras López Rafael
Elizondo Vega Roberto
DJOUAD Farida
Original Assignee
Cells For Cells S A
Consorcio Regenero
Univ Los Andes
Inst Nat Sante Rech Med
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cells For Cells S A, Consorcio Regenero, Univ Los Andes, Inst Nat Sante Rech Med, Univ Montpellier filed Critical Cells For Cells S A
Publication of CL2022001380A1 publication Critical patent/CL2022001380A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0665Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/51Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Células madre mesenquimales con propiedades terapéuticas mejoradas. La presente invención se refiere a un método para la obtención de células madre mesenquimales (MSC) con propiedades de inmunosupresión, condroprotección y condrodiferenciación mejoradas, y capacidad mejorada para promover la proliferación de condrocitos. El método comprende poner en contacto las MSC cultivando MSC en un medio de inducción suplementado con 0,01 a 100 microg/ml de un inhibidor de ATP-sintasa, y retirar los medios de inducción para obtener MSC con actividad mejorada. Además, la presente invención también se refiere a las propias MSC y a su uso con fines de terapia celular preferentemente para el tratamiento de enfermedades autoinmunes y/u osteoarticulares.
CL2022001380A 2019-11-26 2022-05-26 Células madre mesenquimales con propiedades terapéuticas mejoradas CL2022001380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19211428 2019-11-26

Publications (1)

Publication Number Publication Date
CL2022001380A1 true CL2022001380A1 (es) 2023-06-16

Family

ID=68696296

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001380A CL2022001380A1 (es) 2019-11-26 2022-05-26 Células madre mesenquimales con propiedades terapéuticas mejoradas

Country Status (4)

Country Link
US (1) US20220290105A1 (es)
EP (1) EP4065692A4 (es)
CL (1) CL2022001380A1 (es)
WO (1) WO2021105926A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis
WO2025194289A1 (es) * 2024-03-18 2025-09-25 Cells For Cells S.A. Nanovesículas extracelulares de células madre mesenquimales inducidas a metabolismo glicolítico para el tratamiento de osteoartritis
CN120843420A (zh) * 2025-07-01 2025-10-28 中山大学附属第三医院 一种间充质干细胞中的adar1诱导剂及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5723601A (en) * 2000-04-25 2001-11-07 Osiris Therapeutics Inc Joint repair using mesenchymal stem cells
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
EP3719115A4 (en) * 2017-11-27 2021-08-25 Regenero S.A. COMPOSITION AND PROCESS FOR CELL CULTURE, MULTIPLICATION, PRESERVATION AND / OR PRETREATMENT OF CELLS

Also Published As

Publication number Publication date
WO2021105926A2 (en) 2021-06-03
WO2021105926A3 (en) 2021-07-08
EP4065692A2 (en) 2022-10-05
US20220290105A1 (en) 2022-09-15
EP4065692A4 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
CL2022001380A1 (es) Células madre mesenquimales con propiedades terapéuticas mejoradas
Regmi et al. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
Zhang et al. Cyclic mechanical stretching promotes migration but inhibits invasion of rat bone marrow stromal cells
BR112014018524A8 (pt) Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras
CY1121243T1 (el) Χρηση μιας λαμινινης για τη διαφοροποιηση πλειοδυναμων κυτταρων σε κυτταρικες σειρες ηπατοκυτταρων
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
WO2012088225A3 (en) Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
AU2012274478A8 (en) Method for amplifying NK cells
MY183058A (en) Production method for retinal tissue
BR112016009200A8 (pt) uso de um inibidor de btk e um inibidor imune do ponto de verificação
CU24495B1 (es) Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas
JP2016501013A5 (es)
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
ATE480615T1 (de) Verfahren zur proliferation von stammzellen
AR031281A1 (es) Metodos para el tratamiento de trastornos proliferativos celulares
WO2015181831A3 (en) A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord
ES2487465T1 (es) Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos
CA2837895C (en) Methods of treating or preventing neurological diseases
AR125461A1 (es) Células presentadoras de antígeno recombinante
Tan et al. Immunomodulative effects of mesenchymal stem cells derived from human embryonic stem cells in vivo and in vitro
NZ551828A (en) A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins